Cardiology Headline News

In patients with HF and ejection fraction 40% or greater, the absolute risk reduction for total worsening HF events and CV death with finerenone vs. placebo was greatest in those with recent worsening HF, new data from FINEARTS-HF show.

A common question we receive every 4 years is: How will the election impact my investments?

The American Heart Association Scientific Sessions will be held in-person only in Chicago from Nov. 16 to 18 and will feature eight late-breaking science sessions during the 3-day meeting.

Asporin has been discovered as a potential new target that may be used when developing therapeutic interventions for pulmonary arterial hypertension, according to a University of California, Los Angeles (UCLA) press release.

SAN DIEGO — Managing systemic inflammation is critical to reducing cardiovascular and pulmonary outcomes in patients with rheumatoid arthritis, according to a presenter at the 2024 Congress of Clinical Rheumatology West.

Elucid announced it received 510(k) clearance from the FDA for its noninvasive imaging analysis software to help quantify and classify plaque morphology and diagnose CVD.

In a phase 2a trial of patients with obesity-related HF with preserved ejection fraction, a novel controlled metabolic accelerator was associated with weight loss at 3 months compared with placebo.

The FDA approved 18F flurpiridaz, a new cardiac PET perfusion radiotracer, for adult patients with known or suspected coronary artery disease being evaluated for myocardial ischemia and infarction.

A multidisciplinary quality improvement program to prevent cardiac arrest in the pediatric ICU provided sustained improvement in participating centers out to 2 years, researchers reported.

Decreases in body weight and HbA1c induced by GLP-1 receptor agonists and other diabetes drugs can reduce the risk for cardiometabolic complications for adults newly diagnosed with type 2 diabetes, researchers reported.